Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway

Abstract The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are co...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Carlos Chaccour, N. Regina Rabinovich
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2017
Subjects:
Ivermectin
Endectocide
Clinical trials
Clinical development
Anopheles
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/s12936-017-1802-3
https://doaj.org/article/66d12562e1c344e797250bcf2ea43aa8
Description
Summary:Abstract The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.

Similar Items